--- title: "Join Crux Biolabs in Switzerland for a Presentation on “Advantage Australia” and Learn Why International Biotechs Turn to Australia to Accelerate Their Clinical Research - Crux Biolabs" description: "Join Crux Biolabs at Advantage Australia in Zurich on 8 May and learn why biotechs run first in human trials in Australia for speed, savings and quality." canonical: "https://cruxbiolabs.com/news-events/join-crux-biolabs-in-switzerland-for-a-presentation-on-advantage-australia-and-learn-why-international-biotechs-turn-to-australia-to-accelerate-their-clinical-research/" generated: "2026-10-23T02:57:02+00:00" --- [Back to News & Events](https://cruxbiolabs.com/news-events/) Events # Join Crux Biolabs in Switzerland for a Presentation on “Advantage Australia” and Learn Why International Biotechs Turn to Australia to Accelerate Their Clinical Research 12 Apr 2025 By [Stefan Cross](https://cruxbiolabs.com/staff/stefan-cross/) This May, Crux Biolabs is proud to be part of an important conversation—one that may shape the trajectory of early-phase clinical development for biotech and small pharma companies in Switzerland and beyond. And we are inviting you to join us. As part of a joint delegation presenting at *Swiss Biotech Day* in Basel (May 5–6) and a special satellite event in Zurich (May 8), Crux Biolabs will join three other Australian-based organisations—Accelagen, RDI Partners, and Veritus Research—to present a compelling case for why more companies should consider Australia for early-phase clinical research. The Zurich event, titled **“Advantage Australia”**, is designed specifically for companies with preclinical assets that are preparing for first-in-human studies. These pivotal moments are often expensive, high-stakes decisions—and we believe Australia offers a strategic edge that deserves your attention. ### **Why Australia? Timing, Cost, and Quality** While many European companies instinctively look toward the U.S. or other parts of Europe when advancing clinical programs, Australia presents a unique trifecta of advantages: **speed, affordability, and scientific excellence**. Studies in Australia can initiate in as little as six weeks—dramatically faster than the 4–6 month IND timelines common in the U.S. Coupled with up to 43.5% R&D tax incentive, early-phase trials in Australia are often **more cost-effective without sacrificing quality**. Australian trial data is globally accepted and compatible with EMA and FDA submissions, allowing for smooth progression into global development plans. ### **A Full-Service, End-to-End Clinical Ecosystem** The Zurich panel event will showcase how Australian organisations seamlessly collaborate to provide a **turnkey clinical trial experience**. Each of the four presenting companies represents a critical piece of the ecosystem: - **Accelagen** serves as the clinical research organisation (CRO), offering full program oversight, from site selection to recruitment to study completion. - **Crux Biolabs** provides comprehensive bioanalytical services, ensuring reliable, high-quality data collection and interpretation. - **Veritus Research** offers a 42-bed Phase I clinical facility and access to robust healthy volunteer and patient recruitment networks. - **RDI Partners** advises on strategic access to Australia’s R&D tax incentives and financial planning for international sponsors. Together, this panel represents a microcosm of Australia’s broader clinical trial infrastructure, demonstrating just how simple, efficient, and effective running a trial in Australia can be. ### **What to Expect from the Zurich Event** The panel—designed for **biotech and pharma companies on the cusp of human trials**—will take attendees through the entire Australian clinical trial experience. From regulatory nuances to operational workflows and financial incentives, the session will answer the key question: *Why should I consider Australia for my first-in-human program?* This interactive event is not a sales pitch. It’s an **information-sharing session** where industry professionals can ask candid questions, explore specific concerns, and walk away with a clear sense of what working in Australia truly looks like. The session will wrap with informal networking to continue conversations in a more relaxed setting. ### **Why You Should Attend** If you’re evaluating where to take your preclinical asset next, **this event could save you time, money, and headaches**. Australia’s proven track record, streamlined startup timelines, and globally accepted data make it an option worth serious consideration—especially in today’s ever-shifting regulatory and geopolitical climate. As Stefan Cross, CEO of Crux Biolabs, put it: “Every stage of clinical development is a major investment. Taking one hour to explore a faster, more cost-effective alternative with real-world results—it’s not just smart, it’s essential.” --- ### **Join Us in Zurich – May 8** Whether you’re ready to make a move or just beginning to explore your options, *Advantage Australia* is the event to attend. Let us show you why Australia is more than just a destination—it’s an *advantage*. For more information or to register, [click here.](https://events.humanitix.com/advantage-australia-go-further-with-your-early-phase-clinical-trials)